Endometrial cancers

Pathology

Endometrial cancer is a neoplasm that affects the inner lining of theuterus (the endometrium) and is caused by the uncontrolled proliferation of endometrial cells with transformation into malignant cells. It is among the most frequent gynecological cancers, especially in women after menopause, but it can also occur in childbearing age.

Types

For decades there has been talk of two distinct forms of endometrial cancer:

  • Type 1: endometrioid, estrogen-dependent, better prognosis tumor;
  • Type 2: Rare histotype tumor (serous, clear cell, mucinous, undifferentiated), unrelated to estrogen production and with more aggressive behavior.

In recent years, the classification has evolved to include the molecular profile of the tumor.
This approach is based on the analysis of biomolecules expressed by the tumor and allows endometrial cancers to be divided into four prognostically different groups. It also allows more targeted modulation of adjuvant therapies based on aggressiveness and risk of recurrence.

The numbers in Italy

In 2024, according to the AIRTUM (Italian Association of Cancer Registries) registry, endometrial cancer recorded about 8,652 new diagnoses, the third most frequent malignancy in women in the 50-69 age group.

Symptoms

Most endometrial cancers (about 90%) occur with abnormal vaginal bleeding, such as after menopause, or at different times than the normal menstrual cycle in women of childbearing age. Because this symptom often appears early in the disease, about 80% of endometrial cancers are diagnosed early, when the neoplasm is still confined to the uterus.

Other signs, more frequent in advanced stages, may include:

  • Abnormal and foul-smelling vaginal discharge;
  • Pain in the pelvic or lumbar area;
  • Weight loss not related to diet or physical activity;
  • urinary disorders;
  • Alterations in bowel function, such as constipation or diarrhea.

Risk factors

Type 1 endometrial cancer is closely related toexcessive or prolonged estrogen exposure not balanced by progesterone. Several factors can increase the risk of developing it:

Factors related to hormones and the reproductive cycle

    • Hyperestrogenism: excess of circulating estrogen over progesterone, common in obese patients;

    • Early onset of men struation or late menopause, which increase the total number of menstrual cycles and thus estrogen exposure;

    • Absence of pregnancy, which reduces elevated progesterone phases;

    • Hormone replacement therapy with estrogen alone, without the addition of progesterone.

In contrast, the use of the combined birth control pill (estrogen + progesterone) is a protective factor.

Metabolic and lifestyle factors

    • Obesity: adipose tissue produces estrogen, disrupting the normal balance between estrogen and progesterone and increasing the risk of endometrial cancer;

    • diabetes mellitus: metabolic conditions that adversely affect hormone balance;

    • high blood pressure: often associated with metabolic syndrome, which includes obesity and insulin resistance, increasing the risk of endometrial cancer.

Age-related factors

It is a typical cancer in patients over 50 years old, with higher incidence in post-menopausal age.

Genetic and family predisposition

    • Lynch syndrome(a hereditary disease also associated with colorectal cancer and other malignancies) significantly increases the risk of developing endometrial cancer later in life (about 70% compared with 3% in the general population);

    • A family history of endometrial or colon cancer may indicate an increased risk.

Diagnosis and examination

In our institute, patients can access:

  • Level II transvaginal ultrasound scans
  • Integrated Hysteroscopy and Ultrasound Center, where endovaginal ultrasound and hysteroscopy are performed simultaneously for a comprehensive analysis of endometrial pathology.

Suspicion of endometrial cancer is raised when, during gynecological examination and transvaginal ultrasound, an increase in endometrial rhyme thickness is found.

The diagnostic suspicion is then confirmed with an endometrial biopsy. This can be performed withdiagnostic hysteroscopy, an instrument that can visualize the endometrial cavity and perform endometrial biopsies for proper histologic definition.

Once endometrial neoplasia has been diagnosed, it is essential to perform instrumental examinations for staging: transvaginal ultra sound performed by an experienced operator (level II pelvic endovaginal ultrasound), in some cases MRI (MRI of the pelvis), and CT scan of the chest and abdomen. Transvaginal ultrasound and MRI of the pelvis allow local assessment of the endometrium, tumor infiltration, and local extent of disease. CT scan, on the other hand, allows detection of lymph node, peritoneal, or distant metastases.

Therapies

Conservative options in selected cases

In selected cases of very early cancers that have not yet infiltrated the uterus, in women who are pre-menopausal, inoperable, or at a young age or who wish to have children in the future, there is the possibility of using local treatment:

  • progesterone IUDs

  • ventual endometrial ablation by hysteroscopy

These approaches aim to regress the neoplasm while avoiding surgery.

Surgical treatment

Standard treatment for endometrial cancer begins withsurgical removal of the uterus and ovaries by advanced laparoscopic surgery and robotic surgery.

Even in cases of advanced disease at diagnosis, first-line surgical treatment remains the preferred choice, provided the disease is completely removable and the patient is anesthesiologically fit.

What it consists of

While in the past surgical treatment also included pelvic lymphadenectomy (i.e., removal of all lymph nodes in the pelvis and, in some cases, the lumboaortic region), today this approach is being replaced by the sentinel lymph node technique, which is less invasive and has a lower rate of complications.

This technique involveslocating and removing only the first lymphnode that receives lymphatic drainage from the tumor-the so-called “sentinel lymph node”-because it is the most likely point of arrival of any cancer cells.
To identify it, a tracer (such as fluorescent indocyanine green) is injected near the uterus during surgery, allowing the surgeon to visualize and remove only those lymph nodes that are truly at risk. Analysis of this lymph node makes it possible to tell if the disease has spread without having to remove all the lymph nodes, thus reducing the risk of leg swelling (lymphedema) and other postoperative complications.

After surgery and after analysis of the molecular classification of the tumor, other therapeutic strategies such as chemotherapy or radiation therapy will be decided.

 

Post-surgical therapies

After surgery, analysis of the molecular classification of the tumor guides the decision on subsequent therapies, which may include chemotherapy and radiation therapy.

In recent years, experimental studies have shown the efficacy of immunotherapy in certain patient subgroups.

Ongoing support

At our institute, we ensure constant support before, during and after treatment to accompany each patient throughout the entire course of treatment and recovery.

Management of emergencies and side effects

The cancer patient is often a fragile patient, who needs help and support in her disease journey: when she experiences an ailment, whether related to the disease or a side effect of therapy, she needs to be able to receive a specialist’s opinion quickly, through a “fast track.”

For this reason, at the Candiolo Institute there is an assistance service every day, Monday through Friday from 8 a.m. to 5 p.m.: just call the secretary of the Oncology Day Hospital (011 993 3775) reporting the need for an urgent consultation, and the patient is quickly contacted by his or her specialist doctor.

Psychological support

The impact of cancer in a person’s life also affects the psychological sphere: falling ill with cancer is in fact always a traumatic event that affects all dimensions of the person and can generate anxiety, fear, anger, depression.

At the Candiolo Institute, alongside cutting-edge therapies, the treatment and care pathway always includes a qualified psycho-oncological support that helps the patient cope positively not only with treatment but also with the delicate phase of physical and psychological recovery.

It is also possible to participate in support groups psychological to compare with other people who have gone through or are going through the same experience.

Direct line to specialists

To ensure timely and direct support and receive timely answers to concerns and questions, a dedicated support service is in place at the Candiolo Institute for all patients.

From Monday to Friday, from 8 a.m. to 5 p.m., you can contact the secretariat of the oncology day hospital at 011.993.3775, reporting the need for urgent consultation.

The patient will be quickly put in touch with his or her medical specialist, to receive clear answers and immediate support.

Continuing and palliative care

The cancer patient is a person with complex needs that requires multidisciplinary support not only for the cancer disease, but also for all related issues.

At the Candiolo Institute, patients who need or require it have access to specialists in different areas to receive nutritional support, physical therapy, pain therapy and management of other associated conditions.

Social work

The Social Service Department of the Candiolo Institute conducts information and orientation interviews to patients and their families on how to access services in the area and how to obtain welfare and social security benefits provided by law (disability, benefits for aids and prostheses, work leave, etc.).

The service operates on Wednesdays and Fridays from 9 a.m. to 1 p.m. (phone: 011 9933059).

Follow up

With the conclusion of the course of treatment, the follow-up period begins during which, through a series of examinations and visits, the side effects of the therapies performed and their effectiveness are monitored and the patient’s functional recovery is assessed.

Follow-up visits are especially important to intercept any recurrences early, so that appropriate therapy can be intervened. For the patient, they are also a valuable opportunity for dialogue with her medical specialist.

It is the same specialist physician who schedules follow-up visits, in which the patient’s health condition is assessed and reports of any required tests are viewed.

Interdisciplinary Group

Every cancer requires, in all phases of disease management, a multidisciplinary approach that at the Candiolo Institute is guaranteed by a team of different specialists, belonging to the various clinical and surgical departments of the Institute: this team is called GIC (Interdisciplinary Care Group). The GIC ensures that each patient is taken care of throughout the diagnostic-therapeutic process, including prescribing and booking examinations and communicating with the patient and his or her family members. The GIC defines and shares a personalized care pathway for each patient, based not only on the type and stage of the tumor, but also on the patient’s own characteristics. The goal is to ensure that he or she has the best outcome both oncologically and functionally and the maintenance of a good quality of life.The Group also works closely with researchers at the Institute to ensure that patients have rapid access to the latest research-produced innovations in screening, diagnosis and treatment.

Clinical divisions

The diagnostic and therapeutic pathway of endometrial cancers at Candiolo involves several clinical divisions, including:

Clinical studies

Researchers at the Candiolo Institute are involved in numerous projects, both nationally and internationally, dedicated to the study of gynecological cancers. These studies range from clinical and translational to molecular research, including numerous experimental clinical trials of new chemotherapy drugs, as well as innovative therapies such as immunotherapy and hormone therapy.

What makes the Candiolo Institute a landmark in endometrial cancer care is the personalized approach based on risk stratification.

By classifying different tumor types into risk categories, physicians can indicate the most appropriate strategy for each patient: from simple follow-up for low-risk tumors, to hormone therapy or immunotherapy for intermediate-risk cases, to radiation and/or chemotherapy for high-risk tumors. This approach enables targeted and effective care, ensuring that patients receive the most appropriate treatment for their situation.

Access to clinical trials

In selected cases, patients may also have the opportunity to participate in clinical trials that aim to evaluate the efficacy and safety of new surgical techniques, drugs, or innovative therapeutic approaches. Participation in these studies represents an important opportunity to access cutting-edge treatments, always under close medical supervision.

Why choose us

At Candiolo IRCCS Institute, every patient with endometrial cancer is followed according to highly specialized standards, thanks to the synergistic work of a dedicated Interdisciplinary Care Group (ICG) .

Clinical experience and tailored approach

Due to the high number of cases treated each year, the Candiolo Institute is a national reference for taking care of esophageal cancer. Our experience enables us to deal with even the most complex situations, always with a personalized approach built on the clinical and personal profile of each patient.

Imaging technologies and advanced diagnostics

Establishing the treatment plan always starts with an accurate and timely diagnosis. Patients have access to state-of-the-art imaging technologies that allow accurate assessment of the extent of the disease.

In addition, the Institute offers advanced and sophisticated laboratory investigations, including molecular and genomic analyses, which are critical for identifying biological features of cancer and guiding therapeutic decisions.

Minimally invasive surgical techniques and multidisciplinarity

When indicated, surgery is performed with minimally invasive techniques (laparoscopic or thoracoscopic), which reduce operative trauma, promote faster recovery, and improve postoperative quality of life. Every treatment choice is defined within the GIC, ensuring a consistent and integrated approach.

Clinical research and access to trials

As an IRCCS, the Candiolo Institute combines clinical practice with a strong vocation for scientific research. Patients can be evaluated for inclusion in active clinical trials, which represent a real chance to access innovative therapies not yet available in standard practice. Collaboration between care and research is a distinctive value that translates into concrete opportunities for the patient.

Care and support every step of the way

The Interdisciplinary Care Group takes care of the person at every stage: from diagnosis to treatment to follow-up, with attention to nutritional support, psychological health, and reintegration into daily life. The organization of checkups, visits and treatment is designed to ensure continuity and serenity, always valuing the human dimension of care.